Ligand Pharmaceuticals Incorporated (LGND) announced the pricing of an upsized $625 million offering of 0.0% convertible senior notes due 2031 in a private placement to qualified institutional buyers, strengthening the company's financial flexibility and supporting its long-term capital strategy.